TW201311241A - 包含蒙特魯卡斯特(montelukast)及左旋西替利□(levocetirizine)的膠囊調配物 - Google Patents
包含蒙特魯卡斯特(montelukast)及左旋西替利□(levocetirizine)的膠囊調配物 Download PDFInfo
- Publication number
- TW201311241A TW201311241A TW101125301A TW101125301A TW201311241A TW 201311241 A TW201311241 A TW 201311241A TW 101125301 A TW101125301 A TW 101125301A TW 101125301 A TW101125301 A TW 101125301A TW 201311241 A TW201311241 A TW 201311241A
- Authority
- TW
- Taiwan
- Prior art keywords
- capsule formulation
- levocetirizine
- pharmaceutically acceptable
- capsule
- layer
- Prior art date
Links
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 title claims abstract description 68
- 229960001508 levocetirizine Drugs 0.000 title claims abstract description 68
- 239000007963 capsule composition Substances 0.000 title claims abstract description 65
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title claims abstract description 37
- 229960005127 montelukast Drugs 0.000 title claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 20
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 18
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 18
- 208000006673 asthma Diseases 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 201000009961 allergic asthma Diseases 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims description 55
- 239000008187 granular material Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007902 hard capsule Substances 0.000 claims description 22
- 239000007937 lozenge Substances 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- 229960003943 hypromellose Drugs 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000004373 Pullulan Substances 0.000 claims description 4
- 229920001218 Pullulan Polymers 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical group [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 4
- 229960001951 montelukast sodium Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 235000019423 pullulan Nutrition 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 208000036071 Rhinorrhea Diseases 0.000 claims description 3
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 3
- 230000007803 itching Effects 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010041232 sneezing Diseases 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000003679 aging effect Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 9
- 229960001803 cetirizine Drugs 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- -1 amine salt Chemical class 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229960004543 anhydrous citric acid Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 229960003908 pseudoephedrine Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- PGLIUCLTXOYQMV-GHVWMZMZSA-N 2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]piperazine-1,4-diium-1-yl]ethoxy]acetic acid;dichloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-GHVWMZMZSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002590 anti-leukotriene effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 229960003308 levocetirizine dihydrochloride Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
揭示的是一種用於預防或治療過敏性鼻炎以及氣喘之膠囊調配物,其包含二個分開的層:(1)蒙特魯卡斯特(Montelukast)層,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(2)左旋西替利□(LEVOCETIRIZINE)層,包含左旋西替利□或其藥學上可接受鹽;以及其製備方法。如本發明之膠囊調配物可完全地分開二個活性成份,藉此使其等間之反應性最小且改善產物對抗老化作用之安定性,因此可使治療效果最佳。
Description
本發明有關一種用於預防或治療過敏性鼻炎以及氣喘之膠囊調配物,其包含二個分開的層:(1)蒙特魯卡斯特(Montelukast)層,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(2)左旋西替利(Levocetirizine)層,包含左旋西替利或其藥學上可接受鹽;以及其製備方法。
“過敏性鼻炎”意指鼻子黏膜在曝露於過敏原後,由IgE介導的發炎反應所引起之鼻子的徵候病症。過敏性鼻炎包括諸如流鼻涕、鼻塞、鼻子癢、打噴涕、眼睛搔癢等等之症狀。
“氣喘”意指一種氣道發炎引起支氣管黏膜腫脹以及在支氣管中發生肌肉抽搐,使得氣流進出肺受限制之病症。氣喘可引起諸如呼吸短促、嚴重咳嗽以及嚴重的情況下哮喘持續狀態(其甚至可能導致死亡)之症狀。
過敏性鼻炎以及氣喘可能分別地發展;然而有研究顯示,將近60%具過敏性鼻炎之病人亦具有氣喘,而85~95%具氣喘的病人亦患有過敏性鼻炎,指出該二種病患群組間高併發率。因此,需要發展一種複合的組成物,其對於該二種病況之治療具改善的安定性以及治療效率。
蒙特魯卡斯特係一種抑制半胱胺醯基白三烯受體
(CysLT1)之拮抗劑,其用於預防以及治療白三烯介導的疾病。特別地,據報導蒙特魯卡斯特具有治療過敏性鼻炎、異位性皮膚炎、慢性蕁麻疹、鼻竇炎、鼻息肉、慢性阻塞性肺病、包括鼻子性結膜炎之結膜炎、偏頭痛、纖維囊腫、病毒性細支氣管炎等等之效力[見,如S.E.Dahlen,Eur.J.Pharmacol.,533(1-3),40-56(2006)]。另外,包含蒙特魯卡斯特鈉之欣流(MSD)已核淮用於治療成人以及2歲以上之小兒科病人之氣喘,目前可在市面上購得。
西替利(Cetirizine)係(2-(4-((4-氯苯基)苯基甲基)-1-哌嗪基)乙氧基-醋酸,其左旋以及右旋鏡像異構物分別揭示為“左旋西替利”以及“右旋西替利”。
左旋西替利可經由從西替利之外消旋混合物的降解或非對稱合成獲得,如英國專利案第225321號中揭示之習用方法,或美國專利案第4800162號以及第5057427號中揭示之酵素生物催化水解作用之方法。左旋西替利具抗組織胺特性,因此可用作為抗過敏、抗組織胺劑以及抗痙攣劑以及支氣管擴張劑。
國際公開案WO 94/06429揭示一種使用左旋西替利治療季節性以及長期過敏性鼻炎之方法。韓國專利案第926410號揭示一種用於治療過敏性疾病之藥學組成物,其包含一包含西替利之片斷以及一包含假麻黃素之片斷,作為活性成份。然而,該活性成份,西替利以及假麻黃素,之抗過敏疾病氣喘之效力還未被核准。此外,經長使用解鼻充血劑,假麻黃素可能會因反彈反應而使鼻充血惡
化,且可能會導致棘手的藥物引起的鼻炎。因此,建議不要使用超過2個星期。
另外,已有關於呈雙層錠劑形式之藥學組成物之報導,其包含在鹼性條件下係安定的蒙特魯卡斯特鈉以及在酸性條件下係安定的二鹽酸左旋西替利[R.T.Rathod,J.Indian Med.Assoc.,107(8),562-564(2009)]。在該呈錠劑形式之組成物之製備方面,非常難以完全地將蒙特魯卡斯特以及左旋西替利彼此分開。即使是形成雙層錠劑之情況下,亦不可能在物理上完全分開各活性成份。再者,為了製造此等錠劑,需要雙層錠劑之機械。
此外,蒙特魯卡斯特已知在曝露於光、熱或濕氣時係不安定的,且會產生諸如具式(I)之蒙特魯卡斯特亞碸以及具式(II)之蒙特魯卡斯特順式異構物之降解產物。根據M.M.Al Omari等人,當市場可得之欣流(Singulair)口嚼錠曝露於太陽光下時,蒙特魯卡斯特亞碸之數量在3個禮拜後增加2.4%;當配製於0.1M鹽酸溶液中之蒙特魯卡斯特曝露於鈉下時,蒙特魯卡斯特順式-異構物增加14.6%[見M.M.Al Omari et at.,J.Pharm.And Biomed.,45,465-471(2007)]。如報導所示,不容易配製可對抗老化之安定的蒙特魯卡斯特產物。
就物化特性而言,左旋西替利亦不安定,很難製備可對抗老化之安定的產物。左旋西替利有三個主要的降解產物,其包括具式(III)之相關的化合物A、具式(IV)之相關的化合物B以及具式(V)之相關的化合物D。相關的化合物A以及B係左旋西替利經水解製得,而相關的化合物D係左旋西替利經乙基酯加成製得。事實上,在加速安定性條件下,左旋西替利顯示相關的化合物A、B以及D之形成的速率增加,因此不易提供調配物安定性。
因此,本發明已經建立一種用於治療包括過敏性鼻炎以及氣喘之過敏性病症之藥學組成物,其包含蒙特魯卡斯特作為抗白三烯劑,具有良好的安定性,同時行使時無不良反應;以及左旋西替利作為抗組織胺劑,其作用在早期過敏反應,長期使用具有安定性。
因此,本發明之標的係提供一種用於預防或治療過敏性鼻炎以及氣喘之藥學調配物,其包含蒙特魯卡斯特或其藥學上可接受之鹽;以及左旋西替利或其藥學上可接受之鹽。
本發明之另一標的係提供一種製備該藥學調配物之方法。
依照本發明之標的,提供有一種用於預防或治療過敏性鼻炎以及氣喘之膠囊調配物,其包含二個分開的層:(1)蒙特魯卡斯特層,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(2)左旋西替利層,包含左旋西替利或其藥學上可接受之鹽。
依照本發明之另一標的,提供有一種用於製備該膠囊調配物之方法,其包含下列步驟:(i)混合蒙特魯卡斯特或其藥學上可接受之鹽以及一藥學上可接受之添加物,以及將該混合物粒化成顆粒或使該顆粒形成錠劑;以及(ii)混合左旋西替利或其藥學上可接受之鹽以及一藥學上可接受之添加物,以及將該混合物粒化成顆粒或使該顆粒形成錠劑;以及(iii)將步驟(i)中製得之蒙特魯卡斯特之錠劑或顆粒以及步驟(ii)中製得之左旋西替利之錠劑或顆粒,充填於硬膠囊中,在該膠囊中形成分開的層。
依照本發明之說明書,結合顯示本發明之膠囊調配物之概略圖之附圖第1圖,本發明之以上以及其它標的將變得顯而易見。
第1圖顯示本發明之膠囊調配物之概略圖。
在此之後將詳細地說明本發明。
本發明提供一種用於預防或治療過敏性鼻炎以及氣喘之膠囊調配物,其包含二個分開層:(1)蒙特魯卡斯特層,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(2)左旋西替利層,包含左旋西替利或其藥學上可接受之鹽。
在本發明中,該蒙特魯卡斯特層以及左旋西替利層
可獨立地呈顆粒或錠劑的形式。明確而言,本發明之膠囊調配物係藉由下列所製得之膠囊調配物:將(1)包含蒙特魯卡斯特或其藥學上可接受之鹽之蒙特魯卡斯特的錠劑或顆粒;以及(2)包含左旋西替利或其藥學上可接受之鹽之左旋西替利的錠劑或顆粒,充填進入硬膠囊中,在該膠囊中形成二個分開的層。其中,蒙特魯卡斯特層以及左旋西替利層中之至少一個可呈錠劑之形式。
為了預防因水引起之任何不欲之副反應,該蒙特魯卡斯特層以及左旋西替利層可在不使用水或有機溶劑之情況下製得,或在實質上不含水或有機溶劑之條件下製得。該蒙特魯卡斯特層以及左旋西替利層中水含量之數量分別為5%或更少。
本發明之膠囊調配物使用抗組織胺劑左旋西替利作為第一活性成份,用於降低早期的過敏反應,以及使用抗白三烯劑蒙特魯卡斯特作為第二活性成份,用於治療以及預防後期過敏性鼻炎之主要症狀,即鼻塞以及氣喘。
在本發明中用作為第一活性成份之蒙特魯卡斯特或其藥學上可接受之鹽較佳地係蒙特魯卡斯特鈉。蒙特魯卡斯特或其藥學上可接受之鹽每天的劑量為每單位劑型0.4至100mg,較佳地1至50mg,更佳地2.5至20mg。
在本發明中用作為第二活性成份之左旋西替利或其藥學上可接受之鹽係,例如,歐洲專利申請案第0058146號、第0601028號以及第0801064號;英國專利案第2225320號以及第2225321號;美國專利案第5478941號以及國際專
利公開案WO 97/37982所揭示者。左旋西替利之藥學上可接受之鹽可包括,但不限於,藥學上可接受之無毒性有機或無機酸之酸加成鹽,諸如醋酸、檸檬酸、順丁烯二酸、反丁烯二酸、抗壞血酸、鹽酸、氫溴酸、硫酸、磷酸等等之鹽類;金屬鹽(如鈉鹽或鈣鹽)、銨鹽、胺鹽以及胺基酸鹽,較佳地左旋西替利二鹽酸鹽。左旋西替利或其藥學上可接受之鹽的每天劑量為每單位劑型0.4至100mg,較佳地1至50mg,更佳地2.5至20mg。
本發明之二種活性成份具有快速的起效時間、適當的劑量以及較少有害的副作用,因此其等可施用於小兒科病人,且甚至在長期使用時顯示出良好的耐受性以及安全性。
在本發明之膠囊調配物中,該蒙特魯卡斯特層以及該左旋西替利層,更明確地,形成該等層中每一層之錠劑或顆粒,可包含藥學上可接受之稀釋劑。該稀釋劑之適合的例子可包括微晶纖維素、乳糖、Ludipress、甘露醇、磷酸二氫鈣、澱粉、低取代羥丙基纖維素以及其等之混合物。該稀釋劑可使用之數量範圍,以該錠劑或顆粒之總重量為基礎,從約1至約99重量%,較佳地約5至約95重量%。
額外地,形成該等層中每一個之錠劑或顆粒進一步包含藥學上可接受之添加物,如崩散劑、結合劑、安定劑、潤滑劑、著色劑等等。
崩散劑之例子可包括在液態環境中顯示出安定的崩散之材料,其可擇自於由下列所構成之群組:交聯聚乙烯吡咯烷酮(crospovidone)、羧甲澱粉鈉、交聯羧甲基纖维素鈉、
低取代羥丙基纖維素、澱粉、藻酸鹽或其鈉鹽,以及其等之混合物。較佳地,該崩散劑可為交聯聚乙烯吡咯烷酮、羧甲澱粉鈉、交聯羧甲基纖维素鈉、低取代羥丙基纖維素或其混合物。該崩散劑可使用之數量範圍,以該錠劑或顆粒之總重量為基礎,從1至30重量%,較佳地2至15重量%。
該結合劑之例子可包括羥丙基纖維素、羥丙甲纖維素、聚乙烯吡咯烷酮、共聚維酮、聚乙二醇、輕質無水矽酸、合成矽酸鋁、諸如矽酸鈣或矽酸鋁鎂之矽酸鹽衍生物、諸如磷酸氫鈣之磷鹽類、諸如碳酸鈣之碳酸鹽,以及其混合物。該結合劑可使用之數量範圍,以該錠劑或顆粒之總重量為基礎,從1至30重量%,較佳地2至20重量%。
於本發明中使用之安定劑較佳地可為抗氧化劑。使用抗氧化劑會降低因溫度以及濕度引起之不欲的副反應,因此提高對抗老化作用之安定性。抗氧化劑之特別的例子可包括丁基化羥基甲苯(BHT)、丁基化羥基茴香醚(BHA)、抗壞血酸、抗壞血酸棕櫚酸酯、乙二胺四乙酸(EDTA)、焦亞硫酸鈉以及其混合物,較佳地丁基化羥基甲苯。該安定劑可使用之數量範圍,以該錠劑或顆粒之總重量為基礎,從0.01至10重量%,較佳地0.1至5重量%。
該潤滑劑之例子可包括硬脂酸、諸如硬脂酸鈣或硬脂酸鎂之硬脂酸的金屬鹽類、滑石、膠態二氧化矽、糖脂肪酸酯、氫化植物油、高熔點蠟、甘油基脂肪酸酯、甘油二山嵛酸酯以及其混合物。該潤滑劑可使用之數量範圍,以該錠劑或顆粒之總重量為基礎,從0.3至5重量%,較佳地
0.5至3重量%。
另外,各包含蒙特魯卡斯特或左旋西替利層之錠劑可進一步包含一塗層。該塗層可在至少一個擇自於該等錠劑之表面上形成,以便完全地分開蒙特魯卡斯特以及左旋西替利。此時,為了改善蒙特魯卡斯特以及左旋西替利之安定性,該塗層可在不使用水或有機溶劑之情況下製備,或製備成實質上不含水或有機溶劑之水基塗層。
在本發明中,用於該塗層之塗覆基質可為習用的高分子化合物。該塗覆基質之例子可包括甲基纖維素、乙基纖維素、聚乙烯醇、聚乙烯吡咯烷酮、羥乙基纖維素、羥丙甲纖維素,但不限於此。塗覆物質之數量較佳地保持在最小量,以便改善生產效率以及提供具最適合投與之尺寸大小的調配物。因此,該塗覆物質可使用之數量範圍,以該錠劑或顆粒之總重量為基礎,從1至20重量%,較佳地2至10重量%。
在本發明之膠囊調配物方面,該膠囊可為任何慣常用於製藥的硬膠囊。於本發明中使用之硬膠囊物質可包括,如,明膠、羥丙甲纖維素、普魯藍多醣(pullulan)(NP capsTM等等;Capsugel)或聚乙烯醇。在本發明中,具低水含量之羥丙甲纖維素或普魯藍多醣更適宜使活性成份因水引起之降解最小。
在本發明中,該硬膠囊可具有任何用於製藥之慣常的膠囊尺寸大小。內容積隨著硬膠囊之尺寸大小改變:No.00(0.95mL)、No.0(0.68mL)、No.1(0.47mL)、No.2(0.37mL)、
No.3(0.27mL)以及No.4(0.20mL)。為了病人之方便,膠囊之大小較佳地係小型的,然而,由於需充填在膠囊中之質量的限制,用於本發明之膠囊的大小可包括No.0、No.1、No.2、No.3以及No.4,較佳地No.1、No.2以及No.3。
在本發明之一具體例中,該膠囊調配物包含(a)蒙特魯卡斯特錠劑,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(b)左旋西替利錠劑,包含左旋西替利或其藥學上可接受之鹽,其中該錠劑充填於該硬膠囊中。
於本發明之另一具體例中,該膠囊調配物包含(a)蒙特魯卡斯特顆粒,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(b)左旋西替利顆粒,包含左旋西替利或其藥學上可接受之鹽,其中該顆粒充填於該硬膠囊中。
於本發明之另外的具體例中,發明膠囊調配物包含(a)蒙特魯卡斯特錠劑,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(b)左旋西替利顆粒,包含左旋西替利或其藥學上可接受之鹽,其中該錠劑以及顆粒充填於該硬膠囊中。
本發明之膠囊調配物可用於預防或治療過敏性鼻炎以及氣喘,且該過敏性鼻炎可包括諸如流鼻水、鼻塞、鼻子癢、打噴嚏、眼睛搔癢等等。
另外,本發明提供一種用於製備該膠囊調配物之方法,其包含下列步驟:(i)混合蒙特魯卡斯特或其藥學上可接受之鹽以及一藥學上可接受之添加劑,以及將該混合物粒化成顆粒或使該顆粒形成錠劑;(ii)混合左旋西替利或
其藥學上可接受之鹽以及一藥學上可接受之添加劑,以及將該混合物粒化成顆粒或使該顆粒形成錠劑;以及(iii)將步驟(i)中製得之蒙特魯卡斯特之錠劑或顆粒以及步驟(ii)中製得之左旋西替利之錠劑或顆粒,充填於硬膠囊中,在該膠囊中形成分開的層。
在步驟(i)以及(ii)中,顆粒之打錠過程,可依照習用的打錠方法,使用打錠機進行。所製得之錠劑可具有適合的硬度,如平均硬度在1至30kp之範圍內。可在錠劑上形成任何薄膜塗層之前,測量平均硬度。且,假使錠劑係在步驟(i)或(ii)中產生,則該步驟可進一步包含塗覆該錠劑之步驟。
在步驟(iii)中,蒙特魯卡斯特之錠劑以及顆粒以及左旋西替利之錠劑以及顆粒可充填於硬膠囊中,以形成分開的層,其中從蒙特魯卡斯特層以及左旋西替利層中選擇出之至少一個可呈錠劑之形式。
在本發明中製得之膠囊調配物可經口服、舌頭或舌下途徑投與。
本發明之膠囊調配物包含分開地在該硬膠囊中之蒙特魯卡斯特以及左旋西替利,因此完全地分開該二個活性成份。因此,可使二個活性成份間之反應最小,且提高調配物之安定性,因此使治療效率最大。亦有利的是因為,已經存在用於評估單一調配物之時間依賴性安定性之分析方法,亦可用於本發明之調配物,代替建立新的分析方法。
下列範例係用於進一步例示說明本發明,不應用於限制其範疇。
混合蒙特魯卡斯特層中所述之成份,使用具直徑5.5mm之圓形沖頭將該混合物壓成錠劑,獲得蒙特魯卡斯特錠劑。
同時,重覆以上的程序,但使用左旋西替利層中所述
之成份,獲得左旋西替利錠劑。之後,用藉由將Opadry® White(Y-1-7000,Colorcon)溶於蒸餾水中製得之塗覆溶液,塗覆左旋西替利錠劑。最後,將因此獲得之二種錠劑充填至主要由羥丙甲纖維素組成之No.1硬膠囊中,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
重覆範例1之程序,但使用以上蒙特魯卡斯特層中所述之成份以及組成,獲得包含5mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
重覆範例1之程序,但使用以上蒙特魯卡斯特層中所述之成份以及組成,而左旋西替利層中左旋西替利之實際含量為2.5mg,獲得包含5mg之蒙特魯卡斯特以及2.5mg之左旋西替利之膠囊調配物。
重覆範例1中之程序,但使用以上蒙特魯卡斯特層中所述之成份以及組成,獲得包含4mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
混合在蒙特魯卡斯特層中所述之成份,使用具有直徑5.5mm之圓形沖頭將該混合物壓成錠劑,獲得蒙特魯卡斯特錠劑。之後用藉由將羥丙甲纖維素、羥丙基纖維素、二氧化鈦以及紅色氧化鐵溶於蒸餾水中製得之塗覆溶液,塗覆該蒙特魯卡斯特錠劑。
同時,重覆範例1之程序,獲得左旋西替利錠劑。最後,將因此獲得之二種錠劑充填入主要由羥丙甲纖維素組成之No.1便膠囊中,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利左旋西替利之膠囊調配物。
重覆範例5之程序,但使用主要由普魯藍多醣組成之硬膠囊,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
重覆範例5之程序,但使用主要由明膠組成之硬膠囊,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
依照以上蒙特魯卡斯特層中所述之成份以及組成,混合該等成份,以及用將蒙特魯卡斯特以及羥丙基纖維素溶於蒸餾水中製得之結合溶液揉捏,濕式粒化,以20篩孔過篩以及乾燥,獲得蒙特魯卡斯特顆粒。
同時,重覆範例1中之程序,獲得左旋西替利錠劑。最後,將蒙特魯卡斯特顆粒以及左旋西替利錠劑充填於主要由羥丙甲纖維素組成之No.1硬膠中,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
混合蒙特魯卡斯特層中所述之成份,使用具直徑5.5 mm之圓形沖頭將該混合物壓成錠劑,獲得蒙特魯卡斯特錠劑。之後,用將羥丙甲纖維素、羥丙基纖維素、二氧化鈦以及紅色氧化鐵溶於蒸餾水中製得之塗覆溶液,塗覆該蒙特魯卡斯特錠劑。
同時,依照以上左旋西替利層中所述之成份以及組成,混合該成份,以及用將左旋西替利以及羥丙基纖維素溶於蒸餾水中製得之結合溶液揉捏,濕式粒化,以20篩
孔過篩以及乾燥,獲得左旋西替利顆粒。最後,將蒙特魯卡斯特錠劑以及左旋西替利顆粒充填於主要由羥丙甲纖維素組成之No.1硬膠囊中,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
依照以上所述之成份以及組成,混合蒙特魯卡斯特鈉以及左旋西替利二鹽酸,然後用藉由將羥丙基纖維素溶於乙醇中製得之結合溶液揉捏該混合物,濕式粒化,透過
20篩孔過篩,乾燥。之後,於其中加入輕質無水矽酸以及硬脂酸鎂,混合且使用打錠機器壓成錠劑。之後用藉由將羥丙甲纖維素、羥丙基纖維素、二氧化鈦以及紅色氧化鐵溶解於蒸餾水中製得之塗覆溶液,塗覆所產生的蒙特魯卡斯特以及左旋西替利之錠劑,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之複合錠劑。
將比較例1中製得之複合錠劑充填至主要由明膠組成物之硬膠囊中,獲得包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之膠囊調配物。
依照以上所述之成份以及組成,混合該等成份,然後用藉由將蒙特魯卡斯特以及羥丙基纖維素溶於蒸餾水中製得之結合溶液揉捏該混合物,濕式粒化,透過20篩孔過篩,乾燥。之後,於其中加入輕質無水矽酸以及硬脂酸鎂,混合,且使用打錠機器壓成錠劑。
分開地混合左旋西替利、Ludipress、微晶纖維素、交聯羧甲基纖維素鈉、輕質無水矽酸以及硬脂酸鎂,然後將該混合物壓成錠劑,與製得的蒙特魯卡斯特錠劑一起形成雙層錠劑。用藉由將羥丙甲纖維素、羥丙基纖維素、二氧化鈦以及紅色氧化鐵溶於蒸餾水中製得之塗覆溶液,塗覆該雙層錠劑,獲得所產生的包含10mg之蒙特魯卡斯特以及5mg之左旋西替利之雙層錠劑。
將於範例1、5、6以及7以及比較例1以及2中製得之包含蒙特魯卡斯特與左旋西替利之膠囊調配物,貯存在依照下列條件之加速貯存條件下。測量蒙特魯卡斯特以及左
旋西替利之含量的改變以及相關物質(雜質)的數量。結果示於表3至5中。
<加速貯存條件>
貯存條件:包含在HDPE瓶中,40℃,75% RH下
測試期間:起始、1、2、4以及6個月
分析標的:蒙特魯卡斯特以及左旋西替利
<蒙特魯卡斯特與其相關物質之分析條件>
管柱:用於HPLC之Zorbax SB-Phenyl管柱(Agilent Zorbax),具有不鏽鋼管(內徑4.6 mm x長25 cm),充填二異丙基苯乙基矽膠(粒徑:5 μm)
洗提液:A-含有0.1%三氟醋酸(TFA)之水
B-含0.1% TFA之乙腈
檢測器:UV-吸收檢測器(在238nm下吸收)
流速:1.5 mL/min
管柱溫度:25℃
<左旋西替利以及其相關物質之分析條件>
管柱:用於HPLC之Symmetry Shield RP18管柱(Waters),具有不鏽鋼管(內徑4.6 mm x長25 cm),充填十八烷基甲矽烷基矽膠(粒徑:5 μm)
洗提液:A-DW:乙腈:10% TFA=69:30:1(v/v)
B-DWV:乙腈:10% TFA=29:70:1(v/v)
檢測器:UV-吸收檢測器(在230nm下吸收)
流速:1.2 mL/min
管柱溫度:30℃
蒙特魯卡斯特以及左旋西替利之含量變化示於表3中。且,蒙特魯卡斯特相關物質,即蒙特魯卡斯特亞碸以及蒙特魯卡斯特順式異構物之變化,以及左旋西替利相關物質A、B以及D之變化,分別示於表4以及5中。
如表3所示,範例1、5、6以及7之膠囊調配物在6個月後之加速測試條件下,含量減少不顯著,因此展現出異常良好的貯存安定性。相反地,藉由簡單地混合蒙特魯卡斯特以及左旋西替利製得之比較例1之複合錠劑,以及藉由將比較例1之複合錠劑於置於硬膠囊中製得之比較例2之膠囊調配物,顯示在加速貯存條件下歷時6個月,含量減少將近5%或更多。
如表4以及5中所示,在範例1、5、6以及7之膠囊調配物中,在加速測試條件下歷時6個月後,相關物質之增加不顯
著,因此展現出異常良好的貯存安定性。相反地,藉由簡單地混合蒙特魯卡斯特以及左旋西替利製得之比較例1之複合錠劑,以及藉由將比較例1之複合錠劑充填入硬膠囊製得之比較例2之膠囊調配物,在加速測試條件下歷時6個月後,顯示出相關物質增加將近10倍或更多。因此,發現簡單地混合蒙特魯卡斯特以及左旋西替利製得之複合調配物,會因活性成份之物化特徵而使其貯存安定性變差。
雖然本發明係以特別的具體例作說明,但應認清,熟悉此技藝之人士亦可製造出落在由所附之申請專利範圍所界定之本發明之範疇內之各種改質物以及改變物。
第1圖顯示本發明之膠囊調配物之概略圖。
Claims (21)
- 一種用於預防或治療過敏性鼻炎以及氣喘之膠囊調配物,其包含二個分開層:(1)蒙特魯卡斯特(Montelukast)層,包含蒙特魯卡斯特或其藥學上可接受之鹽;以及(2)左旋西替利(Levocetirizine)層,包含左旋西替利或其藥學上可接受之鹽。
- 如申請專利範圍第1項之膠囊調配物,其中該蒙特魯卡斯特層或該左旋西替利層係呈顆粒或錠劑之形式。
- 如申請專利範圍第2項之膠囊調配物,其中該蒙特魯卡斯特層或該左旋西替利層中至少一個係呈錠劑之形式。
- 如申請專利範圍第1項之膠囊調配物,其中該蒙特魯卡斯特層以及該左旋西替利層進一步包含擇自於由下列所構成之群組之藥學上可接受之添加物:稀釋劑、崩散劑、結合劑、安定劑、潤滑劑、著色劑以及其混合物。
- 如申請專利範圍第1項之膠囊調配物,其中該蒙特魯卡斯特層以及該左旋西替利層係在不使用水或有機溶劑之情況下製得,或在實質上不含水或有機溶劑之條件下製得。
- 如申請專利範圍第1項之膠囊調配物,其中該蒙特魯卡斯特層以及該左旋西替利層含水之數量為5%或更低。
- 如申請專利範圍第3項之膠囊調配物,其中該錠劑進一 步包含一塗層。
- 如申請專利範圍第7項之膠囊調配物,其中該塗層係在不使用水或有機溶劑之情況下製備,或製備成實質上不含水或有機溶劑之水基塗層。
- 如申請專利範圍第7項之膠囊調配物,其中該塗層包含擇自於由下列所構成之群組之塗覆基質:甲基纖維素、乙基纖維素、聚乙烯醇、聚乙烯吡咯烷酮、羥乙基纖維素、羥丙甲纖維素以及其混合物。
- 如申請專利範圍第9項之膠囊調配物,其中該塗層基質之數量範圍,以該錠劑之總重量為基礎,從1至20重量%。
- 如申請專利範圍第1項之膠囊調配物,其中該膠囊係硬膠囊。
- 如申請專利範圍第11項之膠囊調配物,其中該膠囊由擇自於由下列所構成之群組之材料製成:羥丙甲纖維素、普魯藍多醣(pullulan)、明膠以及聚乙烯醇。
- 如申請專利範圍第11項之膠囊調配物,其中該膠囊由羥丙甲纖維素或普魯藍多醣製成。
- 如申請專利範圍第1項之膠囊調配物,其中每單劑型中包含該蒙特魯卡斯特或其藥學上可接受之鹽之數量為2.5mg至20mg。
- 如申請專利範圍第1項之膠囊調配物,其中每單劑型中包含左旋西替利或其藥學上可接受之鹽之數量為2.5mg至20mg。
- 如申請專利範圍第1項之膠囊調配物,其中該蒙特魯卡斯特之藥學上可接受之鹽係蒙特魯卡斯特鈉。
- 如申請專利範圍第1項之膠囊調配物,其中該左旋西替利之藥學上可接受之鹽係左旋西替利二鹽酸。
- 如申請專利範圍第1項之膠囊調配物,其中該過敏性鼻炎包含流鼻水、鼻塞、鼻子癢、打噴嚏或眼睛搔癢。
- 一種用於製備如申請專利範圍第1項之膠囊調配物之方法,其包含下列步驟:(i)混合蒙特魯卡斯特(Montelukast)或其藥學上可接受之鹽以及一藥學上可接受之添加劑,以及將該混合物粒化成顆粒或使該顆粒形成錠劑;(ii)混合左旋西替利(Levocetirizine)或其藥學上可接受之鹽以及一藥學上可接受之添加劑,以及將該混合物粒化成顆粒或使該顆粒形成錠劑;以及(iii)將步驟(i)中製得之蒙特魯卡斯特之錠劑或顆粒以及步驟(ii)中製得之左旋西替利之錠劑或顆粒,充填於硬膠囊中,在該膠囊中形成分開的層。
- 如申請專利範圍第19項之方法,其進一步包含塗覆在步驟(i)或(ii)中製得之錠劑。
- 如申請專利範圍第19項之方法,其中該蒙特魯卡斯特層以及該左旋西替利層中之至少一個係呈錠劑之形式。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110070680 | 2011-07-15 | ||
KR1020110111132A KR20130009553A (ko) | 2011-07-15 | 2011-10-28 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201311241A true TW201311241A (zh) | 2013-03-16 |
Family
ID=47839311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW101125301A TW201311241A (zh) | 2011-07-15 | 2012-07-13 | 包含蒙特魯卡斯特(montelukast)及左旋西替利□(levocetirizine)的膠囊調配物 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20140170213A1 (zh) |
EP (1) | EP2731594B1 (zh) |
JP (1) | JP2014520842A (zh) |
KR (2) | KR20130009553A (zh) |
CN (2) | CN107468667A (zh) |
AR (1) | AR087177A1 (zh) |
BR (1) | BR112014000943A2 (zh) |
CL (1) | CL2014000054A1 (zh) |
CO (1) | CO6880062A2 (zh) |
ES (1) | ES2727861T3 (zh) |
HK (1) | HK1246199A1 (zh) |
JO (1) | JO3551B1 (zh) |
MX (1) | MX366509B (zh) |
MY (1) | MY178890A (zh) |
PE (1) | PE20141200A1 (zh) |
RU (1) | RU2606857C2 (zh) |
SA (1) | SA112330689B1 (zh) |
TW (1) | TW201311241A (zh) |
UA (1) | UA112083C2 (zh) |
WO (1) | WO2013012199A1 (zh) |
ZA (1) | ZA201401143B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
KR101418404B1 (ko) | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
RU2677649C2 (ru) * | 2013-02-21 | 2019-01-18 | Глэнмарк Фармасьютикалс Лимитед | Фармацевтические композиции монтелукаста и левоцетиризина |
EP3308835B1 (en) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
AU2014249456B2 (en) | 2013-03-13 | 2018-08-09 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
MX2015011775A (es) * | 2013-03-13 | 2015-12-01 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. |
KR102226833B1 (ko) * | 2013-06-28 | 2021-03-12 | 한미약품 주식회사 | 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형 |
WO2015069203A1 (en) * | 2013-11-06 | 2015-05-14 | Santa Farma Ilaç Sanayi A.Ş. | Capsule comprising rupatadine fumarate and montelukast sodium |
KR101669556B1 (ko) * | 2014-07-02 | 2016-10-28 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제 |
JP6575031B2 (ja) * | 2014-07-28 | 2019-09-18 | 日本ケミファ株式会社 | モンテルカストナトリウム製剤 |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
PL3222279T3 (pl) | 2016-03-21 | 2022-05-09 | Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością | Doustny preparat farmaceutyczny montelukastu i lewocetyryzyny oraz sposób jego wytwarzania |
CN110678555B (zh) | 2017-04-14 | 2023-10-13 | 比利时胶囊公司 | 制作普鲁兰的方法 |
US11576870B2 (en) | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
KR20210152280A (ko) | 2020-06-08 | 2021-12-15 | 주식회사 경보제약 | 몬테루카스트와 레보세티리진을 포함하는 안정성이 향상된 단일 정제 및 이의 제조방법 |
KR102481517B1 (ko) | 2021-08-30 | 2022-12-27 | 주식회사 클라시아 | 약제학적 제제 |
WO2023068839A1 (ko) | 2021-10-21 | 2023-04-27 | 한화제약주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제 |
KR20240045586A (ko) | 2022-09-30 | 2024-04-08 | 주식회사 제뉴원사이언스 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2588188B1 (fr) * | 1985-10-04 | 1988-01-08 | Delalande Sa | Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation |
DE4101873C2 (de) * | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
ATE170749T1 (de) * | 1992-09-24 | 1998-09-15 | Sepracor Inc | Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma |
RU2108787C1 (ru) * | 1993-09-01 | 1998-04-20 | Роммерс С.А.И.С.Ф. | Фармацевтические мягкие капсулы, содержащие лизинхлониксинат, способ их получения |
WO1999032125A1 (en) * | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
KR20090029314A (ko) * | 2001-06-28 | 2009-03-20 | 유씨비 파쉼 소시에떼아노님 | 세티리진 및 슈도에페드린을 포함하는 정제 |
RO122476B1 (ro) | 2001-06-28 | 2009-07-30 | Ucb S.A. | Tabletă conţinând cetirizină şi pseudoefedrină |
CA2559276A1 (en) * | 2004-03-11 | 2005-09-29 | John P. Mullally | Protocol for improving vision |
FR2898492B1 (fr) * | 2006-03-15 | 2008-06-06 | Pierre Fabre Medicament Sa | Comprimes orodispersibles de domperidone |
CN101073563B (zh) * | 2007-02-07 | 2010-10-06 | 西安利君制药有限责任公司 | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 |
WO2009022821A2 (en) * | 2007-08-13 | 2009-02-19 | Hanall Pharmaceutical Company. Ltd | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
RU2405542C2 (ru) * | 2008-11-19 | 2010-12-10 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Мягкая экструзионная капсула, способ приготовления раствора для ее наполнения, способ получения капсул и способ увеличения плотности агаровой оболочки |
WO2010107404A1 (en) * | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
-
2011
- 2011-10-28 KR KR1020110111132A patent/KR20130009553A/ko active Search and Examination
-
2012
- 2012-07-08 JO JOP/2012/0182A patent/JO3551B1/ar active
- 2012-07-11 PE PE2014000056A patent/PE20141200A1/es not_active Application Discontinuation
- 2012-07-11 ES ES12814306T patent/ES2727861T3/es active Active
- 2012-07-11 RU RU2014105577A patent/RU2606857C2/ru not_active IP Right Cessation
- 2012-07-11 WO PCT/KR2012/005506 patent/WO2013012199A1/en active Application Filing
- 2012-07-11 MX MX2014000312A patent/MX366509B/es active IP Right Grant
- 2012-07-11 JP JP2014520123A patent/JP2014520842A/ja active Pending
- 2012-07-11 MY MYPI2014700043A patent/MY178890A/en unknown
- 2012-07-11 BR BR112014000943A patent/BR112014000943A2/pt not_active Application Discontinuation
- 2012-07-11 CN CN201710839356.8A patent/CN107468667A/zh active Pending
- 2012-07-11 US US14/232,433 patent/US20140170213A1/en not_active Abandoned
- 2012-07-11 CN CN201280035070.XA patent/CN103687591A/zh active Pending
- 2012-07-11 EP EP12814306.2A patent/EP2731594B1/en not_active Not-in-force
- 2012-07-13 TW TW101125301A patent/TW201311241A/zh unknown
- 2012-07-13 AR ARP120102542A patent/AR087177A1/es not_active Application Discontinuation
- 2012-07-14 SA SA112330689A patent/SA112330689B1/ar unknown
- 2012-11-07 UA UAA201401447A patent/UA112083C2/uk unknown
-
2014
- 2014-01-09 CL CL2014000054A patent/CL2014000054A1/es unknown
- 2014-02-11 CO CO14028388A patent/CO6880062A2/es unknown
- 2014-02-14 ZA ZA2014/01143A patent/ZA201401143B/en unknown
- 2014-08-29 HK HK18105848.3A patent/HK1246199A1/zh unknown
-
2015
- 2015-11-06 US US14/934,348 patent/US20160089339A1/en not_active Abandoned
-
2018
- 2018-07-27 KR KR1020180088162A patent/KR102006000B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2731594A4 (en) | 2014-12-31 |
KR20180090966A (ko) | 2018-08-14 |
CL2014000054A1 (es) | 2014-07-11 |
US20160089339A1 (en) | 2016-03-31 |
CN107468667A (zh) | 2017-12-15 |
MX2014000312A (es) | 2014-02-19 |
CO6880062A2 (es) | 2014-02-28 |
US20140170213A1 (en) | 2014-06-19 |
RU2606857C2 (ru) | 2017-01-10 |
JO3551B1 (ar) | 2020-07-05 |
KR20130009553A (ko) | 2013-01-23 |
SA112330689B1 (ar) | 2017-03-02 |
UA112083C2 (uk) | 2016-07-25 |
WO2013012199A8 (en) | 2014-02-06 |
MX366509B (es) | 2019-07-11 |
EP2731594A1 (en) | 2014-05-21 |
ES2727861T3 (es) | 2019-10-21 |
RU2014105577A (ru) | 2015-08-27 |
WO2013012199A1 (en) | 2013-01-24 |
HK1246199A1 (zh) | 2018-09-07 |
PE20141200A1 (es) | 2014-09-29 |
AR087177A1 (es) | 2014-02-26 |
BR112014000943A2 (pt) | 2017-02-14 |
MY178890A (en) | 2020-10-21 |
KR102006000B1 (ko) | 2019-08-01 |
EP2731594B1 (en) | 2019-04-24 |
JP2014520842A (ja) | 2014-08-25 |
ZA201401143B (en) | 2015-04-29 |
CN103687591A (zh) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201311241A (zh) | 包含蒙特魯卡斯特(montelukast)及左旋西替利□(levocetirizine)的膠囊調配物 | |
JP4989733B2 (ja) | 口腔内崩壊錠 | |
TWI565482B (zh) | 包含左旋西替利(levocetirizine)或其藥學上可接受鹽以及蒙特魯卡斯特(montelukast)或其藥學上可接受鹽之供經口投藥的穩定藥學調配物 | |
WO2009101940A1 (ja) | 溶出性の改善された錠剤 | |
WO2011019043A1 (ja) | 2種以上の粒子を含有する口腔内速崩壊錠 | |
EP4321156A1 (en) | Film-coated tablet with improved stability containing montelukast or pharmaceutically acceptable salt thereof and levocetirizine or pharmaceutically acceptable salt thereof | |
KR102481517B1 (ko) | 약제학적 제제 | |
KR101843086B1 (ko) | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 | |
RU2677649C2 (ru) | Фармацевтические композиции монтелукаста и левоцетиризина | |
JP7271869B2 (ja) | レボセチリジン含有錠剤 | |
KR101928849B1 (ko) | 베포타스틴 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 제제 | |
JP2010174047A (ja) | 催眠用圧縮成型製剤 | |
EP2543362A1 (en) | Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts |